Last reviewed · How we verify
Iomazenil (IOMAZENIL (123I))
Iomazenil (generic name: IOMAZENIL (123I)) is a iomazenil (123I) drug. It is currently in Phase 2 development.
Iomazenil (123I) works by binding to the benzodiazepine receptor in the brain.
Iomazenil (123I) is a small molecule radiopharmaceutical drug of the iomazenil class. Its exact target is unknown, but it is used in clinical settings. Iomazenil (123I) is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to understand its pharmacokinetic properties, including half-life and bioavailability. As a result, key safety considerations and clinical applications remain unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IOMAZENIL (123I) |
|---|---|
| Drug class | iomazenil (123I) |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key fitting into a lock. Iomazenil (123I) is a small molecule that binds to a specific receptor in the brain, called the benzodiazepine receptor. This binding can help doctors understand how the brain is working and identify potential problems.
Approved indications
Common side effects
Key clinical trials
- Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction (Phase 1)
- Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans (Phase 1)
- Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis (EARLY/Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iomazenil CI brief — competitive landscape report
- Iomazenil updates RSS · CI watch RSS
Frequently asked questions about Iomazenil
What is Iomazenil?
How does Iomazenil work?
What is the generic name of Iomazenil?
What drug class is Iomazenil in?
What development phase is Iomazenil in?
Related
- Drug class: All iomazenil (123I) drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing